Dermatology · Flemington, NJ
NPI
1073552576
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
63 Church St
Flemington, NJ, 08822
Phone (908) 237-4124
Groups this clinician bills Medicare through
Medicare paid, 2024
$155K
3,177 services
Medicare patients, 2024
814
Average age 73
Drug cost, 2024
$630K
1,018 prescriptions
Company payments, 2025
$961
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael J Sisack was code 17003 (destruction skin lesion), 972 times for 207 patients. In total Michael J Sisack billed 3,177 services in 47 codes, and Medicare paid $155K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-05-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 972 | 207 | $5.55 | $5,394 |
| 99213 Office E&M - Established | Office | 708 | 551 | $63.28 | $45K |
| 17000 Destruction Skin Lesion | Office | 429 | 319 | $43.70 | $19K |
| 11102 Skin Biopsy | Office | 256 | 218 | $77.24 | $20K |
| 99214 Office E&M - Established | Office | 135 | 114 | $89.36 | $12K |
| 99203 Office E&M - New | Office | 98 | 98 | $73.95 | $7,247 |
| 17110 Destruction Skin Lesion | Office | 94 | 79 | $91.18 | $8,571 |
| 11103 Skin Biopsy | Office | 88 | 67 | $42.58 | $3,747 |
| 99212 Office E&M - Established | Office | 73 | 68 | $41.25 | $3,011 |
| 99204 Office E&M - New | Office | 46 | 46 | $100.80 | $4,637 |
| 17262 Destruction Skin Lesion | Office | 27 | 19 | $123.48 | $3,334 |
| 69100 Other Organ Systems | Office | 20 | 18 | $53.31 | $1,066 |
| 99202 Office E&M - New | Office | 17 | 17 | $44.19 | $751 |
| 12032 Wound Repair - All Levels | Office | 17 | 16 | $258.33 | $4,392 |
| 11602 Skin Lesion Excision | Office | 12 | 11 | $98.99 | $1,188 |
By year: 2022 $196K for 3,516 services; 2023 $181K for 3,423 services; 2024 $155K for 3,177 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael J Sisack prescribed most often to Medicare patients was Triamcinolone Acetonide, with 123 prescriptions and refills. In total Michael J Sisack wrote 1,018 Medicare prescriptions that cost $630K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 123 | 143 | 78 | $786 |
| Ketoconazole Generic | 97 | 99 | 46 | $1,176 |
| Clobetasol Propionate Generic | 91 | 103 | 66 | $3,437 |
| Doxycycline Hyclate Generic | 73 | 87 | 24 | $1,509 |
| Metronidazole Generic | 58 | 70 | 39 | $2,425 |
| Dutasteride Generic | 52 | 85 | 11 | $1,149 |
| Fluorouracil Generic | 47 | 47 | 45 | $2,880 |
| Mometasone Furoate Generic | 40 | 48 | 33 | $769 |
| Minoxidil Generic | 31 | 57 | Under 11 | $247 |
| Hydrocortisone Generic | 31 | 31 | 19 | $192 |
| Mupirocin Generic | 29 | 29 | 24 | $233 |
| Pentoxifylline Generic | 20 | 34 | Under 11 | $448 |
| Clindamycin Phos-Benzoyl Perox Clindamycin Phos/Benzoyl Perox | 19 | 19 | Under 11 | $1,399 |
| Opzelura Ruxolitinib Phosphate | 18 | 18 | Under 11 | $35K |
| Spironolactone Generic | 18 | 40 | Under 11 | $241 |
Brand drugs: 108 claims; generic drugs: 910 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael J Sisack $961 ($961 in general payments such as food, travel and fees) from 13 companies. The largest payer was Abbvie Inc. with $223.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 13 | $223 |
| Galderma Laboratories, L.P. GALD.SW | 20 | $176 |
| Janssen Biotech, Inc. JNJ | 10 | $172 |
| Pfizer Inc. PFE | 6 | $96.3 |
| UCB, Inc. UCB.BR | 4 | $82.68 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $67.9 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $32.19 |
| Almirall LLC | 1 | $22.81 |
| Incyte Corporation INCY | 1 | $19.29 |
| Amgen Inc. AMGN | 1 | $18.91 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.